# A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

> **NCT04412564** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** TQ-B3101

## Key facts

- **NCT ID:** NCT04412564
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-05
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-09
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04412564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04412564, "A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04412564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*